Senti BiosciencesSNTI
About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Employees: 48
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
34% more capital invested
Capital invested by funds: $2.41M [Q3] → $3.23M (+$824K) [Q4]
14% more funds holding
Funds holding: 14 [Q3] → 16 (+2) [Q4]
3.21% less ownership
Funds ownership: 23.27% [Q3] → 20.06% (-3.21%) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for SNTI.
Financial journalist opinion
Based on 5 articles about SNTI published over the past 30 days









